secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001740797-24-000049
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant Technologies appoints Chris Winter as COO; receives quarterly RSA of 100,000 shares
--------------------------------------------------------------------------------

- Chris Winter appointed COO effective Nov 1, 2024; reports directly to the Board.
- Compensation: quarterly RSA of 100,000 shares (67,000 prorated first quarter) at 85% of 30-day VWAP, floor $0.10.
- Company pays tax gross-up bonus within 10 days of each share issuance.
- Shares fully vested upon issuance; accelerated vesting on change of control (≥50% sale).
- No relocation required; employee uses own laptop and phone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079724000049/0001740797-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079724000049/form8k_avai.htm
  HTML page:      https://secwatch.observer/filing/0001740797-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer